Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5253556> ?p ?o }
Showing triples 1 to 45 of
45
with 100 triples per page.
- Q5253556 subject Q16391411.
- Q5253556 subject Q22948482.
- Q5253556 subject Q6407955.
- Q5253556 subject Q6762709.
- Q5253556 subject Q8506963.
- Q5253556 subject Q8798629.
- Q5253556 abstract "Delcath Systems, Inc. Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly-traded specialty pharmaceutical and medical device company that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine).".
- Q5253556 wikiPageExternalLink 20070530006062.html?.v=1.
- Q5253556 wikiPageExternalLink www.delcath.com.
- Q5253556 wikiPageWikiLink Q1148337.
- Q5253556 wikiPageWikiLink Q12078.
- Q5253556 wikiPageWikiLink Q1216998.
- Q5253556 wikiPageWikiLink Q131257.
- Q5253556 wikiPageWikiLink Q16391411.
- Q5253556 wikiPageWikiLink Q180614.
- Q5253556 wikiPageWikiLink Q181876.
- Q5253556 wikiPageWikiLink Q1981276.
- Q5253556 wikiPageWikiLink Q204711.
- Q5253556 wikiPageWikiLink Q2071287.
- Q5253556 wikiPageWikiLink Q22948482.
- Q5253556 wikiPageWikiLink Q2298283.
- Q5253556 wikiPageWikiLink Q253623.
- Q5253556 wikiPageWikiLink Q30612.
- Q5253556 wikiPageWikiLink Q3414040.
- Q5253556 wikiPageWikiLink Q348922.
- Q5253556 wikiPageWikiLink Q356033.
- Q5253556 wikiPageWikiLink Q420207.
- Q5253556 wikiPageWikiLink Q5167908.
- Q5253556 wikiPageWikiLink Q5425270.
- Q5253556 wikiPageWikiLink Q5425274.
- Q5253556 wikiPageWikiLink Q621636.
- Q5253556 wikiPageWikiLink Q640448.
- Q5253556 wikiPageWikiLink Q6407955.
- Q5253556 wikiPageWikiLink Q664846.
- Q5253556 wikiPageWikiLink Q6762709.
- Q5253556 wikiPageWikiLink Q7167198.
- Q5253556 wikiPageWikiLink Q7446275.
- Q5253556 wikiPageWikiLink Q7896131.
- Q5253556 wikiPageWikiLink Q8506963.
- Q5253556 wikiPageWikiLink Q8798629.
- Q5253556 wikiPageWikiLink Q9368.
- Q5253556 wikiPageWikiLink Q974135.
- Q5253556 comment "Delcath Systems, Inc. Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly-traded specialty pharmaceutical and medical device company that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide.".
- Q5253556 label "Delcath Systems".
- Q5253556 homepage www.delcath.com.